- Home
- NUVB vs TRVI Comparison
NUVB vs TRVI Comparison
Compare NUVB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- TRVI
- Stock Information
- Founded
- NUVB 2018
- TRVI 2011
- Country
- NUVB United States
- TRVI United States
- Employees
- NUVB N/A
- TRVI N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- NUVB Health Care
- TRVI Health Care
- Exchange
- NUVB Nasdaq
- TRVI Nasdaq
- Market Cap
- NUVB 1.6B
- TRVI 1.4B
- IPO Year
- NUVB N/A
- TRVI 2019
- Fundamental
- Price
- NUVB $4.62
- TRVI $11.80
- Analyst Decision
- NUVB Strong Buy
- TRVI Strong Buy
- Analyst Count
- NUVB 7
- TRVI 9
- Target Price
- NUVB $8.86
- TRVI $20.72
- AVG Volume (30 Days)
- NUVB 9.4M
- TRVI 1.6M
- Earning Date
- NUVB 11-03-2025
- TRVI 11-13-2025
- Dividend Yield
- NUVB N/A
- TRVI N/A
- EPS Growth
- NUVB N/A
- TRVI N/A
- EPS
- NUVB N/A
- TRVI N/A
- Revenue
- NUVB $26,748,000.00
- TRVI N/A
- Revenue This Year
- NUVB $283.17
- TRVI N/A
- Revenue Next Year
- NUVB $340.98
- TRVI N/A
- P/E Ratio
- NUVB N/A
- TRVI N/A
- Revenue Growth
- NUVB 1137.19
- TRVI N/A
- 52 Week Low
- NUVB $1.54
- TRVI $2.36
- 52 Week High
- NUVB $5.55
- TRVI $11.86
- Technical
- Relative Strength Index (RSI)
- NUVB 55.23
- TRVI 65.61
- Support Level
- NUVB $4.45
- TRVI $10.22
- Resistance Level
- NUVB $5.17
- TRVI $11.82
- Average True Range (ATR)
- NUVB 0.44
- TRVI 0.59
- MACD
- NUVB -0.05
- TRVI -0.01
- Stochastic Oscillator
- NUVB 44.17
- TRVI 87.88
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.